StreetInsider.com News Articles

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Tue, 03 Feb 2026 08:55:00 -0500

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant.

"Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?' Without exception, the answer has been an enthusiastic 'Yes'. When Dr. Hsiang answered that question, he added something I have

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Tue, 03 Feb 2026 08:55:00 -0500

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Fri, 16 Jan 2026 12:26:00 -0500

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA).

Hemostemix' team included Thomas Smeenk, CEO; Dr. Ina Sarel, Chief Scientific Officer; Dr. Fraser Henderson, Chief Medical Officer, Professor of Neurosurgery and a practicing neurosurgeon; Dr. Ernst von Schwarz, a triple board-certified transplant

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Fri, 16 Jan 2026 12:26:00 -0500

Hemostemix raises $480,000 in private placement at $0.12 per share

Wed, 31 Dec 2025 14:40:14 -0500

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) completed a non-brokered private placement raising CDN$480,000 through the issuance of 4 million common shares at $0.12 per share, according to a company statement.

The Calgary-based stem cell therapy company said proceeds will fund general working capital purposes, including regulatory, clinical and commercialization initiatives for ACP-01, its autologous angiogenic cell therapy platform.

All securities issued under the private placement are subject to a statutory hold period under applicable securities laws and TSX Venture Exchange policies. The placement requires final acceptance by the TSXV.

Hemostemix develops autologous stem cell treatments derived from patients' own blood for

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

Wed, 31 Dec 2025 14:38:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceeds of CDN$480,000, through the issuance of 4,000,000 common shares of the Company at a price of $0.12 per common share.

The proceeds from the private placement will be used for general working capital purposes, including

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

Wed, 31 Dec 2025 14:38:00 -0500

The proceeds from the private placement will be used for general working capital purposes, including

Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01

Tue, 23 Dec 2025 09:10:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physician Education Lead, and to its Scientific Advisory Board (SAB), effective January 2026.

Dr. Alper will work with Hemostemix on a focused set of physician-led education and clinical engagement initiatives, engaging with

Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01

Tue, 23 Dec 2025 09:10:00 -0500

Dr. Alper will work with Hemostemix on a focused set of physician-led education and clinical engagement initiatives, engaging with

Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)

Thu, 11 Dec 2025 09:40:00 -0500

Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum Mechanics, cosmology, and string theory.

Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, is pleased to announce that Thomas Smeenk, BA, has published a major theoretical manuscript introducing the Conformal Consciousness Hypothesis (CCH) —

Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)

Thu, 11 Dec 2025 09:40:00 -0500

Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum Mechanics, cosmology, and string theory.

Hemostemix Grants Stock Options

Thu, 11 Dec 2025 08:57:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix.

Of the Options granted, 663,000 vest immediately and 330,000 vest as to 50% on December 11, 2025 and 50% on December 11, 2026. All options were granted with an exercise price of $0.09 per common

Hemostemix Grants Stock Options

Thu, 11 Dec 2025 08:57:00 -0500

Of the Options granted, 663,000 vest immediately and 330,000 vest as to 50% on December 11, 2025 and 50% on December 11, 2026. All options were granted with an exercise price of $0.09 per common

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

Wed, 10 Dec 2025 11:17:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP-01 at Doctors Hospital, Nassau, The Bahamas, is pleased to announce two major corporate developments:

The U.S. Food and Drug Administration (FDA) has scheduled Hemostemix's basket protocol Pre-IND meeting for January 16, 2026; and
Subject to TSXV approval, the Company

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

Wed, 10 Dec 2025 11:17:00 -0500

The U.S. Food and Drug Administration (FDA) has scheduled Hemostemix's basket protocol Pre-IND meeting for January 16, 2026; and
Subject to TSXV approval, the Company

Hemostemix appoints Shaune Harding as director of patient care

Thu, 04 Dec 2025 09:12:11 -0500

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announced the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. The Calgary-based stem cell therapeutics company said Harding will oversee patient onboarding, medical records management, and continuous monitoring of patients in treatment programs.

In her role, Harding will manage comprehensive medical records review and HIPAA-compliant transfer of patient records to treating physicians. She will also oversee patient health-journey mapping from initial assessment through treatment and multi-year follow-up periods.

The position includes responsibility for continuous patient data monitoring through approved wearable devices such as Fitbit Sense 2, which

Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations

Thu, 04 Dec 2025 09:10:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee:

On-boarding of all new patients entering Hemostemix treatment programs;
Comprehensive medical records review and HIPAA-compliant transfer of patient records to the treating physician team;
Patient health-journey mapping, from initial assessment through treatment and multi-year follow-up;
Continuous patient data monitoring, including heart rate, activity, exercise, and

Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations

Thu, 04 Dec 2025 09:10:00 -0500

On-boarding of all new patients entering Hemostemix treatment programs;
Comprehensive medical records review and HIPAA-compliant transfer of patient records to the treating physician team;
Patient health-journey mapping, from initial assessment through treatment and multi-year follow-up;
Continuous patient data monitoring, including heart rate, activity, exercise, and

Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14

Wed, 03 Dec 2025 14:05:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements.

Hemostemix will highlight its unprecedented clinical trial results in cardiovascular disease including Chronic Limb-Threatening Ischemia (CLTI)—a field where the standard of care has remained largely unchanged for decades. With four published clinical studies validating ACP-01's ability to regenerate

Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14

Wed, 03 Dec 2025 14:05:00 -0500

Hemostemix closes $518,440 private placement, to attend DFCon

Tue, 02 Dec 2025 09:12:17 -0500

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announced it will participate in DFCon 2025 in San Antonio, Texas, and completed a private placement financing of $518,440.

The company will attend the American Limb Preservation Society conference, which focuses on diabetic foot care, vascular medicine, and limb preservation. The three-day event expects more than 500 delegates including podiatrists, vascular surgeons, and other medical professionals.

Hemostemix plans to present data on its ACP-01 treatment, also known as VesCell, for vascular and ischemic conditions. The company cited results from a University of Toronto published phase II clinical trial showing 0% mortality and 83% limb

Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Tue, 02 Dec 2025 09:10:00 -0500

Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeons, wound-care experts, infectious disease specialists, endocrinologists/diabetologists, cardiovascular and endovascular specialists, nurses, NPs, PAs, residents, fellows, physical therapists, and industry innovators.

"VesCell saves diabetic limbs from amputation, and that

Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Tue, 02 Dec 2025 09:10:00 -0500

"VesCell saves diabetic limbs from amputation, and that

Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

Wed, 26 Nov 2025 16:21:00 -0500

Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemix for 2,000,000 shares each, subject to adjustment and TSXV approval.

This marks the first of many acquisitions, as Hemostemix's long-term strategy to acquire profitable, accretive medical practices within which is can add

Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

Wed, 26 Nov 2025 16:21:00 -0500

This marks the first of many acquisitions, as Hemostemix's long-term strategy to acquire profitable, accretive medical practices within which is can add